GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aceragen Inc (NAS:ACGN) » Definitions » Cost of Goods Sold

Aceragen (Aceragen) Cost of Goods Sold : $0.00 Mil (TTM As of Mar. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Aceragen Cost of Goods Sold?

Aceragen's cost of goods sold for the three months ended in Mar. 2023 was $0.00 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Aceragen's Gross Margin % for the three months ended in Mar. 2023 was 100%.

Cost of Goods Sold is also directly linked to Inventory Turnover.


Aceragen Cost of Goods Sold Historical Data

The historical data trend for Aceragen's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aceragen Cost of Goods Sold Chart

Aceragen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aceragen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aceragen Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aceragen  (NAS:ACGN) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Aceragen's Gross Margin % for the three months ended in Mar. 2023 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(2.47 - 0) / 2.47
=100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Aceragen's Inventory Turnover for the three months ended in Mar. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Aceragen Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Aceragen's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Aceragen (Aceragen) Business Description

Traded in Other Exchanges
N/A
Address
505 Eagleview Boulevard, Suite 212, Exton, PA, USA, 19341
Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.
Executives
Vincent Milano director, officer: President & CEO C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Maxine Gowen director
Pillar Invest Corp director, 10 percent owner C/O PILLAR INVEST OFFSHORE SAL, STARCO CENTER, BLOC B FL3, OMAR DAOUK ST, BEIRUT M8 2020-3313
Atul Chopra 10 percent owner C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
John Clayton Taylor director, officer: Chief Executive Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Carl N Kraus officer: Chief Medical Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Andrew R Jordan officer: Chief Strategy Officer C/O GUILFORD PHARMACEUTICALS INC, 6611 TIBUTARY ST., BALTIMORE MD 21224
Daniel Salain officer: Chief Operating Officer C/O GRAYBUG VISION, INC., 275 SHORELINE DRIVE, SUITE 450, REDWOOD CITY CA 94065
Ronald J Wooten director
Nq Pof V Gp, Ltd. director, other: See Remarks 4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
Novaquest Co-investment Fund Xv, L.p. director, other: See Remarks 4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
John J. Kirby officer: V.P. of Finance, PFO & PAO C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341
Michael R Dougherty director C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Elizabeth Ann Tarka officer: Chief Medical Officer 111 WAVERLY CIRCLE, PHOENIXVILLE PA 19460
Bryant David Lim officer: SVP & General Counsel C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341

Aceragen (Aceragen) Headlines

From GuruFocus

Aceragen Announces Recommendation of Data Monitoring Committee in Terra Study

By Stock market mentor Stock market mentor 02-06-2023